Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80630 |
Name | B-lymphoblastic leukemia/lymphoma |
Definition | A B-cell acute lymphoblastic leukemia that is characterized by the presence of too many B-cell lymphoblasts in the blood and bone marrow. |
Source | DiseaseOntology.org |
Alt Ids | DOID:7061 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS G12D | Anti-CD19 CAR-T cells | B-lymphoblastic leukemia/lymphoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02883049 | Phase III | Dasatinib Dexamethasone + Doxorubicin Prednisone Vincristine Sulfate Thioguanine Cytarabine Mercaptopurine Leucovorin Methotrexate Pegaspargase Etoposide Clofarabine | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | Active, not recruiting | USA | NZL | IRL | CHE | CAN | AUS | 1 |
NCT02981628 | Phase II | Inotuzumab ozogamicin | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Recruiting | USA | 1 |
NCT04690595 | Phase I | BAFFR-CAR T cells | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | Recruiting | USA | 0 |
NCT05327894 | Phase III | Blinatumomab | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) | Recruiting | SWE | SVK | NOR | NLD | LTU | ITA | IRL | HUN | FRA | FIN | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
NCT05674175 | Phase Ib/II | CART22-65s cells + huCART19 | Co-administration of CART22-65s and huCART19 for B-ALL | Recruiting | USA | 0 |
NCT06343311 | Phase Ib/II | EB103 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) | Recruiting | USA | 0 |